However, existing studies have found that the incidence of adverse events such as elevated ALT and neutropenia in children treated with PEG IFNα is similar to that in adults.[19,22] In this case, the patient was closely monitored with appropriate prevention measures in place, and no significant abnormalities in physiological indicators and examinations were observed throughout the study. This evidence concerns the gene IFNA2 and Decreased total neutrophil count.